Acute lung injury after blood transfusion in mechanically ventilated patients.
Gajic O, Rana R, Mendez JL, et al.
Transfusion 2004;44(10):1468-1474.
Review by
Increased local procoagulant action: a mechanism contributing to the favorable hemostatic effect of recombinant FVIIa in PLT disorders.
Galan AM, Tonda R, Pino M, Reverter JC, Ordinas A, Escolar G
Transfusion 2003;43(7):885-892.
Review by
The use of recombinant factor VIIa in children with inherited platelet function disorders.
Almeida AM, Khair K, Hann I, Liesner R
Br J Haematol 2003;121(3):477-481.
Review by Aldouri M
Intraoperative use of recombinant activated coagulation factor VII. [Editorial]
Weiskopf RB
Anesthesiology 2002;96(6):1287-1289.
Review by
The use of recombinant factor VIIa in a Jehovah’s Witness with auto-immune thrombocytopenia and post-splenectomy haemorrhage.
Waddington DP, McAuley FT, Hanley JP, Summerfield GP
Br J Haematol 2002;119(1):286-288.
Review by Aldouri M
Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage.
Gerotziafas GT, Zervas C, Gavrielidis G, et al.
Am J Hematol 2002;69(3):219-222.
Review by M. Aldouri
NATA: Network for the Advancement of Patient Blood Management, Haemostasis and Thrombosis
MISSION: Providing a multidisciplinary forum for dialogue between haematologists, transfusion medicine specialists, anaesthesiologists, intensive care and emergency physicians, surgeons, perfusionists, nurses, biomedical scientists and other healthcare professionals.
Sitemap
Contact us
- secretary@nataonline.com
-
NATA
Rue de l’Industrie 24
1040 Bruxelles - VAT: 0781668659